8-K
filed June 15, 2023, 7:59 PM ET
ticker VNOV
CIK 0001699709
M&A
confidence high
sentiment neutral
materiality 0.75
VitaNova Life Sciences Corp (VNOV): M&A transaction — Xianchang Ma acquires 86.3% of Yijia Group; appointed CEO, President, CFO and Director
VitaNova Life Sciences Corp
- Barry Sytner sold 5,066,250 shares (86.3% of outstanding) to Xianchang Ma for $470,562 on June 14, 2023.
- Sytner resigned as CEO, President, CFO, and Director; Ma appointed to all those roles effective June 14, 2023.
- Xianchang Ma, age 48, is CEO and director of Tengjun Biotechnology Corp; founded Jinan Tengiun Biological Technology in 2014.
- Purchase price paid from Ma's personal funds; agreement included escrow and conditions such as filing of Form 10-K.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Xianchang Ma was appointed as President at VitaNova Life Sciences Corp.
- Action
- appointed
- Role
- President
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barry Sytner resigned as Chief Executive Officer at VitaNova Life Sciences Corp.
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barry Sytner resigned as President at VitaNova Life Sciences Corp.
- Action
- resigned
- Role
- President
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barry Sytner resigned as Chief Financial Officer at VitaNova Life Sciences Corp.
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Xianchang Ma was appointed as Director at VitaNova Life Sciences Corp.
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Xianchang Ma was appointed as Chief Financial Officer at VitaNova Life Sciences Corp.
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barry Sytner resigned as Director at VitaNova Life Sciences Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Xianchang Ma was appointed as Chief Executive Officer at VitaNova Life Sciences Corp.
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
VitaNova Life Sciences Corp underwent a change of control involving Xianchang Ma for $470,562 (closed 2023-06-14).
- Action
- change of control
- Counterparty
- Xianchang Ma
- Consideration
- $470,562
- Closing
- 2023-06-14
Exact text from the filing
of common stock of the Company to Mr. Ma, constituting approximately 86.3% of the issued and outstanding shares of the Company as of May 2, 2023, for a total consideration of $470,562, derived from the purchaser’s personal funds. The Securities Purchase Agreement was closed on June 14, 2023. Following the closing, Mr. Ma acquired a beneficial interest in
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.